These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8799418)

  • 1. Serum CA19-9 determination in the management of pancreatic cancer.
    van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
    Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
    Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
    Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
    Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic head carcinoma: clinical analysis of 189 cases.
    Hua YP; Liang LJ; Peng BG; Li SQ; Huang JF
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):79-84. PubMed ID: 19208521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA19-9 serum concentrations--analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival.
    Klapdor R; Bahlo M; Babinski A; Klapdor S
    Anticancer Res; 2010 May; 30(5):1869-74. PubMed ID: 20592394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of CA 19-9 serum course in pancreatic cancer.
    Safi F; Schlosser W; Falkenreck S; Beger HG
    Hepatogastroenterology; 1998; 45(19):253-9. PubMed ID: 9496523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumor markers in skeletal metastasis.
    Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
    Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.